CEL-SCI Corporation

Dedicated to research and development directed at improving the treatment of cancer, autoimmune and infectious diseases.


Learn More About Us

CEL-SCI is a pioneer in cancer immunotherapy. Our Phase III clinical trial in head and neck cancer tests the idea that we should boost the immune system BEFORE the ravages of surgery, radiation and chemotherapy because that is when the immune system is strongest. The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled. With the last patient enrolled in the study in September 2016, final data read-out based on 298 events is expected in the near future.

Use your immune system to fight disease. That's the root of CEL-SCI’s mission.

Technology

We strive to create real value for our stakeholders by developing innovative therapies that have the potential to address unmet medical needs.

CEL-SCI's vision is to change the way cancer is treated.


Investor Information

CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases.

Use your immune system to fight disease. That's the root of CEL-SCI’s mission.


Product Pipeline

CEL-SCI’s idea and aim is to help cancer patients by boosting their immune system BEFORE the ravages of surgery, radiation and chemotherapy. We believe that boosting a cancer patient's immune system while it is still intact, should provide the greatest possible impact on survival. Our Phase 3 study is meant to prove this.

CEL-SCI's vision is to change the way cancer is treated.


Meet Our Team

The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.

“CEL-SCI has a dedicated and passionate team that believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival when it comes to cancer immunotherapy.”

Geert R. Kersten